Biome Grow Stock EBITDA

BIOIF Stock  USD 0.01  0  94.74%   
Biome Grow fundamentals help investors to digest information that contributes to Biome Grow's financial success or failures. It also enables traders to predict the movement of Biome Pink Sheet. The fundamental analysis module provides a way to measure Biome Grow's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biome Grow pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Biome Grow Company EBITDA Analysis

Biome Grow's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Biome Grow EBITDA

    
  313.61 K  
Most of Biome Grow's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biome Grow is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Biome Grow reported earnings before interest,tax, depreciation and amortization of 313.61 K. This is 99.96% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all United States stocks is 99.99% higher than that of the company.

Biome EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biome Grow's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Biome Grow could also be used in its relative valuation, which is a method of valuing Biome Grow by comparing valuation metrics of similar companies.
Biome Grow is currently under evaluation in ebitda category among its peers.

Biome Fundamentals

About Biome Grow Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Biome Grow's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biome Grow using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biome Grow based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Biome Pink Sheet

Biome Grow financial ratios help investors to determine whether Biome Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biome with respect to the benefits of owning Biome Grow security.